Several recent reports have suggested that community-associated meticillin-resistant Staphylococcus aureus (MRSA) clones, particularly those harbouring genes for Panton-Valentine leukocidin (PVL) or toxic shock syndrome toxin 1 (TSST-1), are increasingly responsible for infections in hospitals. Here, a retrospective study was carried out to investigate whether antimicrobial resistance patterns could be used to detect these pathogens in a French university hospital. Isolates were characterized by antimicrobial susceptibility testing, PCR profiling (PVL genes and tst), PFGE typing and multilocus sequence typing. Demographic and clinical data were collected from all patients. For PVL-positive MRSA, the typical antimicrobial resistance pattern (susceptible to fluoroquinolones, non-susceptible to fusidic acid, kanamycin resistant and susceptible to gentamicin and tobramycin) had a sensitivity of 77.8 % and a positive predictive value (PPV) of 100 %. For tst-positive MRSA, the antimicrobial resistance pattern (susceptible to fluoroquinolones and non-susceptible to fusidic acid) had a sensitivity of 100 % and a PPV of 72.4 %. These results suggest that phenotypic rules based on antimicrobial resistance patterns are potentially useful for the detection of PVL-and tst-positive MRSA isolates.
INTRODUCTION
Since the early 1970s, meticillin-resistant Staphylococcus aureus (MRSA) has spread throughout the world, becoming highly endemic in many geographical areas. This major nosocomial pathogen is associated with high rates of morbidity and mortality in hospitals worldwide (Cosgrove et al., 2005) . Until recently, the French MRSA problem was limited to hospitals, and MRSA infections were mostly acquired in hospital units (Robert et al., 2005) . The emergence of community-associated MRSA (CA-MRSA) producing Panton-Valentine leukocidin (PVL) in patients with no recognized risk factors for MRSA infection is a source of particular concern (Vandenesch et al., 2003; Diep et al., 2006) . Most PVL-producing MRSA strains isolated in France belong to a single clone of sequence type 80 (ST80) (Vandenesch et al., 2003) . However, another MRSA clone, producing toxic shock syndrome toxin 1 (TSST-1), belonging to ST5 has recently been detected in France and Switzerland, in community-acquired infections in some cases (van der Mee-Marquet et al., 2003; Durand et al., 2006) . The antimicrobial resistance patterns of these clones are relatively stable. Both are susceptible to fluoroquinolones (Robert et al., 2005; Durand et al., 2006) , whereas most nosocomial MRSA strains isolated in French hospitals are resistant to fluoroquinolones (Thouverez et al., 2003; Bertrand et al., 2004) . Thus, antimicrobial resistance pattern may be a powerful marker for detecting PVLand TSST-1-producing MRSA. We aimed to determine whether a laboratory hospital surveillance programme based on antimicrobial resistance patterns could identify these pathogens efficiently. Molecular typing and detection of mecA and toxin genes. Nonduplicate MRSA isolates susceptible to fluoroquinolones (FQS-MRSA) were collected. For each FQS-MRSA, two non-duplicate MRSA isolates resistant to fluoroquinolones (FQR-MRSA) from the same year were randomly selected. Isolates were genotyped by determining their total DNA macrorestriction pattern by PFGE (CHEF DRIII; Bio-Rad) using SmaI, as described previously (Bertrand et al., 2000) . We used GelCompar software (Applied Maths) to establish a DNA similarity matrix based on the Dice coefficient (262 strain comparisons). A dendrogram was constructed using the unweighted pair-group method for clustering arithmetic averages with the Dice coefficient. We ensured that the gels were comparable by including S. aureus NCTC 8325 as a reference, and results were interpreted according to international recommendations: isolates with no more than six fragment differences were considered to be subtypes of a pulsotype (belong to the same clone) (Tenover et al., 1995) . For PCR methods, genomic DNA was extracted using standard procedures. Sequences specific for the mecA gene, PVL genes (lukS-PV and lukF-PV) and the tst gene (encoding TSST-1) were detected by PCR, as described elsewhere (Jarraud et al., 2002) . Multilocus sequence typing was performed for one randomly selected isolate of the major PFGE patterns as described previously (Enright et al., 2000) .
METHODS
Data for patients. For each MRSA isolate included, data concerning the bacterial isolate (site of isolation and date of sampling) and the patient (age, sex, location of care and date of admission) were collected by reviewing the patient's medical records. We also determined whether the MRSA isolate met the Centers for Disease Control and Prevention (CDC) definition for CA-MRSA (Buck et al., 2005) : 'lack of exposure to the healthcare environment' (specimen for culture obtained during an outpatient visit or within 48 h of hospitalization from patients with no history of the following: surgery, hospitalization, dialysis or admission to a long-term care facility within the previous year, presence of an indwelling catheter or a percutaneous medical device at the time of culture specimen collection or previous isolation of MRSA).
Data analysis. Data were compiled in an electronic Excel database. We evaluated the value of antimicrobial resistance patterns as a marker of PVL-and/or tst-positive MRSA strains by determining the performance characteristics of several combinations of antimicrobial resistance. We assessed the significance of differences between groups by carrying out Student's t-test or a Mann-Whitney U-test for continuous variables, as appropriate, and Fisher's exact test or a Pearson x 2 test for categorical variables. All analyses were two-tailed and a P value of less than 0.05 was considered significant. We used Stata software version 10.0 for the analysis.
RESULTS
From January 2004 to December 2007, 4622 non-duplicate isolates of S. aureus were recovered from clinical specimens in our hospital. We identified 962 of these isolates as MRSA strains, 56 of which were susceptible to fluoroquinolones (5.8 % of all MRSA isolates) ( Table 1) . Forty-nine (87.5 %) of these isolates were available for study. These 49 isolates and 98 randomly selected FQR-MRSA isolates contained the mecA gene. Nine FQS-MRSA isolates contained PVL genes (two, three, one and three in 2004, 2005, 2006 and 2007, respectively) and 21 FQS-MRSA isolates contained the tst gene (three, seven, seven and four in 2004, 2005, 2006 and 2007, respectively) . None of the FQS-MRSA isolates were positive for both toxin genes and all FQR-MRSA isolates were negative for these genes. Twenty-eight of the 29 isolates (96.6 %) susceptible to fluoroquinolones but not to fusidic acid produced either PVL (n57) or TSST-1 (n521). Moreover, PVL-positive MRSA isolates had a specific aminoglycoside resistance pattern: they were resistant to kanamycin and susceptible to gentamicin and tobramycin ( Table 2 ). The tst-positive MRSA isolates (n521) were either susceptible to gentamicin and resistant to both kanamycin and tobramycin (61.9 %) or susceptible to all three aminoglycosides (38.1 %). Seven of the nine PVL-positive MRSA isolates displayed the following typical antimicrobial resistance pattern: susceptibility to fluoroquinolone but not to fusidic acid, resistance to kanamycin and susceptibility to gentamicin and tobramycin. The performance characteristics of this antimicrobial resistance pattern as a phenotypic system for detecting and predicting PVL production by MRSA isolates were as follows (Table 3) : sensitivity577.8 % [95 % confidence interval (CI) 40.2-96.1] and positive predictive value (PPV)5100 % (95 % CI 56.1-100). For TSST-1-positive MRSA isolates, an antimicrobial resistance pattern consisting of susceptibility to fluoroquinolones but not to fusidic acid gave a sensitivity of 100 % (95 % CI 80.8-100) and a PPV of 72.4 % (95 % CI 52.5-86.6). If we took into account susceptibility to aminoglycosides, then the major pattern observed, consisting of susceptibility to gentamicin and resistance to both kanamycin and tobramycin, gave a sensitivity of 61.9 % (95 % CI 38.7-81.0) and a PPV of 92.9 % (95 % CI 64.2-99.6). (Dauwalder et al., 2008) . Thirdly, PVL-or tst-positive MRSA isolates were characterized by a specific antimicrobial resistance pattern that was readily detectable over time. The proportion of MRSA isolates carrying PVL toxin genes was similar to that reported in a previous study of 12 French hospitals, including Besançon Hospital, between 1999 and 2003 (0.4-1.0 %) , suggesting stability over time (Robert et al., 2005) . We also found that only approximately half of these isolates (5/9) fulfilled the CDC definition for CA-MRSA; this finding is consistent with the results of several studies demonstrating that this entirely epidemiological definition is now of little use in distinguishing CA-MRSA from hospital-acquired MRSA isolates (Millar et al., 2007; David et al., 2008) . Durand et al. (2006) suggested that tst-positive clones are acquired in both hospitals and the community in France. Our results seem to support this assertion: 19 % of tst-positive MRSA isolates were classified as CA-MRSA according to the CDC definition. This invasion of the hospital setting by PVL-and tst-positive MRSA isolates constitutes a new challenge in terms of treatment and infection control strategies.
This study had several limitations. Firstly, it was a retrospective study, and prospective validation of these phenotypic rules is required. Secondly, this study was performed at a single centre, limiting the generalization of our findings. Lastly, random sampling of 98/906 FQR-MRSA is a small sample and does not exclude the possibility that FQR-MRSA may contain PVL or tst genes.
Despite these limitations, the development of phenotypic rules based on antimicrobial resistance patterns for predicting the presence of particular virulence factors may be a suitable approach to use in routine microbiological analyses. These rules should be reassessed frequently over time. Previous reports suggest that our findings may be extended to French MRSA and the European situation (Robert et al., 2005; Durand et al., 2006; Witte et al., 2007; Dauwalder et al., 2008; Otter & French, 2008) and that microbiologists should be aware that MRSA isolates with a specific antimicrobial resistance pattern (susceptible to FQ and resistant to fusidic acid) are associated with the production of PVL or TSST-1. Jappe et al. (2008) stated in a recent report that 'in contrast to CA-MRSA from other continents, fusidic acid resistance represents a typical marker for the widespread CA-MRSA ST80 in Europe, especially in Germany'.
The dissemination of PVL-producing clones has been reported extensively. The 'USA300' clone has become the principal cause of community-onset S. aureus skin and soft-tissue infections in a number of areas of the USA, and the European ST80 clone has also spread widely throughout Greece and Algeria (Chini et al., 2006; Bekkhoucha et al., 2009) . The spread of tst-positive MRSA clones has been described less frequently. In a recent study, Dauwalder et al. (2008) reported that a tst-positive clone (the Geraldine clone) and the European ST80 clone accounted for 6.3 and 3.6 % of invasive MRSA isolates collected in France, respectively. We also recovered twice as many isolates from the Geraldine clone as from the European ST80 clone. The spread of such clones associated with potentially lethal infections (both PVL and TSST-1) and with potent superantigenic activity (TSST-1) or the ability to cause more serious and recurrent infections (PVL) is of major concern. Recognition of these MRSA clones is essential for the implementation of effective measures to control their spread.
